Beclomethasone arm* (N=193) | Placebo arm† (N=192) | P value | |

Primary endpoint achievement in the total population | |||

Primary endpoint achieved (n=193*, 192†) | 24 | 26 | 0.8 |

Primary endpoint achievement in subpopulations | |||

Subpopulations on the severity of COVID-19 on admission | |||

Asymptomatic (n=13*, 12†) | 0 | 1 | 0.5‡ |

Mild disease (n=122*, 123†) | 16 | 18 | 0.7§ |

Moderately disease (n=58*, 57†) | 8 | 7 | 0.8§ |

Subpopulations on age | |||

Less than 60 years (n=114*, 113†) | 7 | 8 | 0.8‡ |

60 years or more (n=79*, 78†) | 17 | 18 | 0.9‡ |

Subpopulations on the number of COVID-19 vaccines received before contracting COVID-19 | |||

Zero doses (n=71*, 78†) | 11 | 15 | 0.7‡ |

One dose (n=48*, 44†) | 4 | 7 | 0.3‡ |

Two doses (n=74*, 70†) | 9 | 4 | 0.3‡ |

*Beclomethasone arm.

†Placebo arm.

‡Fisher’s exact test.

§Pearson’s χ

^{2}test.ICU, intensive care unit; n, sample size.